FUTURE OF HEALTH: CARDONE VENTURES PARTNERS WITH REVIV TO LAUNCH THE WORLD'S FIRST PRECISION NUTRITION SYSTEM IN THE UK

FUTURE OF HEALTH: CARDONE VENTURES PARTNERS WITH REVIV TO LAUNCH THE WORLD'S FIRST PRECISION NUTRITION SYSTEM IN THE UK

LONDON, Jan. 23, 2025 /PRNewswire/ -- Cardone Ventures, the business growth and investment firm led by Brandon Dawson and Grant Cardone, is proud to announce the UK launch of the world's first patented 10X Precision Nutrition System in partnership...

DeepRoute.ai Showcases the Latest Smart Driving Technology at Automotive World Tokyo 2025 After a Milestone Year

DeepRoute.ai Showcases the Latest Smart Driving Technology at Automotive World Tokyo 2025 After a Milestone Year

TOKYO, Jan. 23, 2025 /PRNewswire/ -- DeepRoute.ai is excited to announce its participation in Automotive World Tokyo 2025, where CEO Maxwell Zhou has been invited to deliver a keynote speech on the paradigm shift in autonomous driving empowered by...

FOR SALE BY EXPRESSION OF INTEREST PRESTIGIOUS DISTRICT 19 RESIDENTIAL DEVELOPMENT OPPORTUNITY IN JALAN NAUNG

FOR SALE BY EXPRESSION OF INTEREST PRESTIGIOUS DISTRICT 19 RESIDENTIAL DEVELOPMENT OPPORTUNITY IN JALAN NAUNG

SINGAPORE, Jan. 23, 2025 /PRNewswire/ -- Brilliance Capital Pte. Ltd. is pleased to announce the launch of an exceptional residential development site located in the tranquil and prestigious enclave of Jalan Naung, Singapore, via an Expression of...

TiltPlay Launches as a Gaming Platform on the Soneium Ecosystem

TiltPlay Launches as a Gaming Platform on the Soneium Ecosystem

"The Game is On" TAIPEI, Jan. 23, 2025 /PRNewswire/ -- TiltPlay, a gaming platform offering fast-paced and engaging casual games, is proud to announce its official launch on the Soneium ecosystem. This launch positions TiltPlay as dynamic,...

Cadonilimab (PD-1/CTLA-4) Phase III Data for First Line Treatment of Advanced Gastric Cancer Published in Nature Medicine

Cadonilimab (PD-1/CTLA-4) Phase III Data for First Line Treatment of Advanced Gastric Cancer Published in Nature Medicine

HONG KONG, Jan. 23, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") is excited to announce that the prestigious medical journal Nature Medicine published the results of the company's independently developed PD-1/CTLA-4...

Pictor Biotech Inc. (d.b.a. SOLARBIOTECH), GPC Bio, and Eleszto Genetika Announce Strategic Unification

Pictor Biotech Inc. (d.b.a. SOLARBIOTECH), GPC Bio, and Eleszto Genetika Announce Strategic Unification

NORTON, Va., LA ROCHELLE, France and BUDAPEST, Hungary, Jan. 23, 2025 /PRNewswire/ -- Today, SOLARBIOTECH, GPC Bio, and Eleszto Genetika proudly announced their acquisition and strategic unification under a single ownership. This consolidation...

FriendliAI and Hugging Face Announce Strategic Partnership

FriendliAI and Hugging Face Announce Strategic Partnership

Developers will be able to utilize FriendliAI's accelerated generative AI infrastructure service to deploy and serve models in the Hugging Face Hub REDWOOD CITY, Calif., Jan. 22, 2025 /PRNewswire/ -- FriendliAI, a leader in accelerated generative AI...

Supported by the Luxembourg Government, The Luxembourg House of Financial Technology (LHoFT) and the Asian Development Bank (ADB) Announce the 2nd Edition of Catapult | SE Asia 2025

Supported by the Luxembourg Government, The Luxembourg House of Financial Technology (LHoFT) and the Asian Development Bank (ADB) Announce the 2nd Edition of Catapult | SE Asia 2025

Fintechs with impact backed by Government Initiative LUXEMBOURG, Jan. 22, 2025 /PRNewswire/ -- The Luxembourg House of Financial Technology (LHoFT) announces the second edition of Catapult: Inclusion Southeast Asia, an acceleration program dedicated...

Lakeside Secures New Distribution Agreements with Kelun Pharmaceutical

Lakeside Secures New Distribution Agreements with Kelun Pharmaceutical

Expanding Partnerships with Major Industry Players ITASCA, Ill., Jan. 21, 2025 /PRNewswire/ -- Lakeside Holding Limited ("Lakeside" or the "Company") (Nasdaq: LSH), a U.S.-based cross-border supply chain solution provider with a unique focus on the...

TAHO Pharmaceuticals Completes Pivotal Trial of TAH3311, the First Oral Dissolving Film Anticoagulant

TAHO Pharmaceuticals Completes Pivotal Trial of TAH3311, the First Oral Dissolving Film Anticoagulant

TAIPEI, Jan. 21, 2025 /PRNewswire/ -- TAHO Pharmaceuticals is pleased to announce the successful completion of the pivotal trial for TAH3311, the first anticoagulant oral dissolving film (ODF). This trial was conducted following detailed discussions...

  • 1
  • ...
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • ...
  • 35
  • menu
    menu